Welcome to our dedicated page for XTL Biopharmaceuticals Ltd. American Depositary Shares news (Ticker: XTLB), a resource for investors and traders seeking the latest updates and insights on XTL Biopharmaceuticals Ltd. American Depositary Shares stock.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) is a clinical-stage biotech company dedicated to advancing pharmaceutical products for the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE) and Sjogren's syndrome. The company's lead candidate, hCDR1, is a promising synthetic peptide comprising approximately 20 amino-acid residues. This Phase II-ready asset has demonstrated significant potential in three clinical trials involving 400 patients and over 200 preclinical studies. Remarkably, the data has been published in more than 40 peer-reviewed scientific journals, underscoring its robust clinical foundation.
XTL Biopharmaceuticals Ltd is also developing Recombinant Human Erythropoietin (rHuEPO), a therapeutic agent known for its efficacy in treating various forms of anemia, including those related to kidney disease and cancer. Currently, rHuEPO is being investigated for its potential to enhance the survival of patients with advanced multiple myeloma (MM).
Given the limited effectiveness and significant side effects of existing SLE treatments, hCDR1 represents a potentially transformative solution for patients suffering from this debilitating condition. XTL Biopharmaceuticals Ltd. is committed to addressing unmet medical needs, leveraging its innovative pipeline to bring new hope to patients worldwide.
XTL Biopharmaceuticals (NASDAQ: XTLB) has completed the acquisition of THE SOCIAL PROXY , an AI web data company, expanding its IP portfolio. The transaction involved XTL acquiring all of Social Proxy's share capital in exchange for ADSs representing 44.6% of XTL's issued share capital and a $430,000 cash payment. Additionally, XTL completed a private placement of $1.5 million to support growth and financial needs.
Social Proxy will operate as a fully owned subsidiary of XTL, with its shareholders appointing two representatives to XTL's board of directors. This acquisition aligns with XTL's strategy to expand its asset portfolio in high-potential areas, particularly in the AI Web Data market. The move is expected to add significant value to XTL and its shareholders.
XTL Biopharmaceuticals announced a definitive agreement to acquire The Social Proxy, an AI web data company. The deal involves issuing shares equating to 44.6% of XTL's issued share capital and paying $430,000. The acquisition aims to enhance XTL's asset portfolio with high-potential assets. The Social Proxy will operate as a subsidiary, with its shareholders appointing two board members. The transaction includes a $1.5 million private placement approved by shareholders, subject to closing conditions. XTL aims to leverage The Social Proxy's advanced IP-based platform for AI and BI applications.
FAQ
What is the current stock price of XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB)?
What is the market cap of XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB)?
What is XTL Biopharmaceuticals Ltd. known for?
What is the lead drug candidate of XTL Biopharmaceuticals Ltd.?
What makes hCDR1 a significant candidate in SLE treatment?
What other products is XTL Biopharmaceuticals Ltd. developing?
What phase is hCDR1 currently in?
What conditions does rHuEPO treat?
How many clinical trials has hCDR1 undergone?
Where can I find published data on hCDR1?
What type of company is XTL Biopharmaceuticals Ltd.?
Is XTL Biopharmaceuticals Ltd. publicly traded?
